新冠假病毒（SARS-CoV-

发布日期：2025-01-04 11:31    点击次数：73

药诺基因--新冠SARS-CoV-2 (2019nCoV)假病毒一站式服务平台 新冠SARS-CoV-2假病毒及Spike蛋白突变株（D614G, S943P, V367F, G476S,V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E: D839Y, D839N, D839E）   产品货号：GM-2019nCoV-PSV01~PSV13 报告基因：RFP和Firefly Luciferase效应细胞：hACE2-HEK293T (Cat.GM-SC-293T-hACE201)包  装：0.5mL/管   产品介绍     药诺基因提供的新冠SARS-CoV-2假病毒（GM-2019nCoV-PSV01~PSV13）是含有Spike蛋白的慢病毒颗粒，用于模拟SARS-CoV-2感染细胞和细胞侵入。SARS-CoV-2假病毒颗粒基因组编码荧光素酶（Firefly Luciferase）和红色荧光蛋白（RFP）。在SARS-CoV-2假病毒进入表达ACE2的细胞后，Firefly Luciferase和RFP则会强表达。人源 ACE2过表达的HEK293T稳转细胞系通常被用来作为效应细胞(GM-SC-293T-hACE2-01。药诺基因提供的新冠SARS-CoV-2假病毒可用于SARS-CoV-2相关疫苗的疗效评估，中和抗体，多肽阻断剂竞争中和试验，还有组织特异性感染测定等。     新冠SARS-CoV-2假病毒及Spike蛋白突变株产品列表       Catalog No. Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants and Effector cells GM-2019nCoV-PSV01-2 SARS-CoV-2 Pseudotyped virus packaging and production GM-SC-293T‐hACE2-01 Human ACE2 overexpression stable HEK293T cell lines GM-2019nCoV-PSV02 Spike D614G mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV03 Spike S943P mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV04 Spike V367F mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV05 Spike G476S mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV06 Spike V483A mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV07 Spike H49Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV08 Spike Q239K mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV09 Spike A831V mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV10 Spike P1263L mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV11 Spike D839Y/N/E-D839Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV12 Spike D839Y/N/E-D839N mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV13 Spike D839Y/N/E-D839E mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV14 P2-mutated Spike protein trimer variant (P2-mutant, S1/S2 cleavage site (furin cleavage sequence)-mutant, (trimerization modified) mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV15 Spike of SARS-COV-2 B.1.1.7 lineage mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV16 Spike(S1+S2) N501Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV17 Spike(S1+S2)-HV 69-70 Deletion mutation(ΔH69/ΔV70) SARS-CoV-2(2019nCoV) Pseudotyped virus GM-2019nCoV-PSV18 Spike(S1+S2)-E484K mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (501Y.V2 lineage) GM-2019nCoV-PSV19 Spike (S1+S2) RBD triple mutation(K417N, E484K and N501Y) of SARS-CoV-2(2019nCoV) Pseudotyped virus (501Y.V2 lineage) GM-2019nCoV-PSV20 Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage Pseudotyped virus GM-2019nCoV-PSV21 Spike (S1+S2) RBD triple mutation(K417T, E484K and N501Y)+D614G of SARS-CoV-2(2019nCoV) Pseudotyped virus (Brazilian P.1 lineage) GM-2019nCoV-PSV22 Spike whole mutant SARS-CoV-2(2019nCoV) Brazilian P.1 lineage Pseudotyped virus GM-2019nCoV-PSV23 Spike(S1+S2) RBD-S477N mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage; 20A.EU2 lineage) and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV24 Spike (S1+S2) RBD mutation (S477N)+ D253G of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV25 Spike (S1+S2) RBD mutation (E484K)+ D253G of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV26 Spike whole mutant SARS-CoV-2(2019nCoV) B.1.526 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV27 Spike(S1+S2) RBD-E484Q mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV28 Spike (S1+S2) RBD mutation L452R of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV29 Spike (S1+S2) RBD mutation (E484Q+L452R) of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV30 Spike whole mutant SARS-CoV-2(2019nCoV) double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India) Pseudotyped virus production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV31 Spike(S1+S2) RBD-S477G mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV32 Spike(S1+S2) RBD-T478K mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (delta variant B.1.617.2 lineage) and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV33 Spike (S1+S2) RBD mutation (L452R+T478K) of SARS-CoV-2(2019nCoV) Pseudotyped virus (delta variant B.1.617.2 lineage) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV34 Spike whole mutant SARS-CoV-2(2019nCoV) delta variant B.1.617.2 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV35 Spike (S1+S2) RBD mutation L452Q of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV36 Spike(S1+S2) RBD mutation F490S of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV37 Spike (S1+S2) RBD mutation (L452Q+F490S) of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV38 Spike whole mutant SARS-CoV-2(2019nCoV) lambda variant C.37 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV39 Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV40 Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus production and Pseudovirus Based Neutralization Assay       新的突变系SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage    目前，COVID-19疫情在全世界各地爆发，严重影响了人类的生活和生命健康。最近出现一种新的突变系称为“Omicron variant aka B.1.1.529 lineage”，最早在2021年11月9号收集的样本中出现。Omicron variant aka B.1.1.529 lineage具有大量突变，很多突变位点值得关注。下图和表是Omicron variant aka B.1.1.529 lineage spike区域的突变点: Figure. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes1. Note: In our product, N211I→Δ211.   Spike Mutation in SARS-COV-2 (2019nCOV)  Omicron variant aka B.1.1.529 lineage Spike-S1 Subunit N Terminal A67V   Δ69-70   T95I   G142D   Δ143-145   Δ211-212   ins214EPE   Spike-RBD G339D Important residues mutation Important residues mutation S371L S373P S375F K417N N440K G446S S477N T478K E484A Q493R G496S Q498R N501Y Y505H Spike-S1 Subunit T547K   D614G A popular mutation in different new SARS-CoV-2 lineage H655Y   N679K   P681H   Spike-S2 Subunit N764K   D796Y   N856K   Q954H   N969K   L981F   Table. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes. GeneMedi为中和抗体开发提供SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage假病毒（pseudotype virus）  Cat No. Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants  GM-2019nCoV-PSV39 Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529) production and Pseudovirus Based Neutralization Assay GM-2019nCoV-PSV40 Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus production and Pseudovirus Based Neutralization Assay GeneMedi为开发和评价抗病毒化合物提供SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein)蛋白 Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Source (Expression Host) GMP-V-2019nCoV-Mpro001 Recombinant 2019nCoV antigen-coronavirus Main Proteinase (Mpro, 3CLpro, His Tag) E.coli GeneMedi提供SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage中和抗体 Cat No. Neutralizing antibody Name Source (Expression Host) GMP-V-2019nCoV-SnAb006 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) Mammalian (human cell) GMP-V-2019nCoV-SnAb007 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) Mammalian (human cell) GMP-V-2019nCoV-SnAb008 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) Mammalian (human cell) GeneMedi提供SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage of Spike蛋白， Spike S-trimer蛋白及ACE2蛋白 Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Source (Expression Host) GMP-V-2019nCoV-Smu-027 Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD mutant (Omicron variant aka B.1.1.529) Mammalian (human cell) GMP-V-2019nCoV-S-trimer-004 Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer Protein (Omicron variant aka B.1.1.529  lineage) with furin cleavage site mutation & T4 fibritin trimerization motif Mammalian (human cell) GMP-H-ACE2001 Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-His) Mammalian (human cell) GMP-H-ACE2002 Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-FC) Mammalian (human cell) GeneMedi提供密码子优化的SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage Spike及Spike RBD的pcDNA3.1(+)、腺病毒、慢病毒载体.  Cat No. Gene &Vector description of 2019 nCoV Vector Tag Coden Optimized GMV-V-2019nCoV-192 pGM-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 pcDNA3.1(+) No tag coden optimized for mamamlian GMV-V-2019nCoV-193 Ad-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Pre-made adenovirus C-3FLAG coden optimized for mamamlian GMV-V-2019nCoV-194 pGMLV-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Lentiviral vector C-3FLAG coden optimized for mamamlian GMV-V-2019nCoV-195 pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 pcDNA3.1(+) No tag coden optimized for mamamlian GMV-V-2019nCoV-196 Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Pre-made adenovirus C-3FLAG coden optimized for mamamlian GMV-V-2019nCoV-197 pGMLV-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Lentiviral vector C-3FLAG coden optimized for mamamlian     《药诺基因protocol-基于新冠假病毒的抗体及疫苗筛选及中和性效价评估》 申请     邮件至 [email protected]申请邮件格式：主题：《药诺基因protocol-基于新冠假病毒的抗体及疫苗筛选及中和性效价评估》 申请 邮件内容：申请人姓名：申请人手机：邮箱：单位：     药诺基因SARS-CoV-2 新冠假病毒细胞进入实验      图注:药诺基因提供的SARS-CoV-2(2019nCoV)假病毒感染HEK293T细胞72小时后，利用荧光(A)、流式细胞 分析(B)和荧光素酶活性(C)实验验证假病毒进入细胞的效率。实验结果表明hACE2显著提高了SARS-CoV-2 PSV的感染效率。药诺基因提供的SARS-CoV-2假病毒为SARS-CoV-2感染、疫苗疗效评估和中和抗体效价检 测等提供了良好的工具。     联系方式     张小姐 Email: [email protected] Tel: +86-21-50478399